• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

达沙替尼引起的胸腔和心包积液。

Dasatinib-Induced Pleural and Pericardial Effusions.

作者信息

Hailan Yousef M, Elyas Ahmed, Abdulla Mohammad A, Yassin Mohamed A

机构信息

Internal Medicine, Hamad Medical Corporation, Doha, QAT.

Cardiology and Cardiovascular Surgery, Heart Hospital, Hamad Medical Corporation, Doha, QAT.

出版信息

Cureus. 2021 Oct 25;13(10):e19024. doi: 10.7759/cureus.19024. eCollection 2021 Oct.

DOI:10.7759/cureus.19024
PMID:34824936
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8611763/
Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disease associated with the Philadelphia chromosome and fusion gene. Tyrosine kinase inhibitors (TKI) are now the standard therapy for this condition. Among the approved TKIs for CML is dasatinib. We present a case of a 58-year-old Egyptian male who developed bilateral pleural (grade II) as well as pericardial effusions (grade II) secondary to dasatinib 100 mg once-daily dosing. He was managed by interrupting dasatinib and introducing diuretics and steroids. The objective is to raise awareness about this unfavorable effect as it may affect the patient's quality of life and increase rates of treatment withdrawal.

摘要

慢性髓性白血病（CML）是一种与费城染色体和融合基因相关的骨髓增殖性疾病。酪氨酸激酶抑制剂（TKI）目前是这种疾病的标准治疗方法。达沙替尼是已获批用于治疗CML的TKI之一。我们报告一例58岁埃及男性病例，该患者因每日一次服用100 mg达沙替尼继发双侧胸腔积液（II级）以及心包积液（II级）。通过中断达沙替尼并使用利尿剂和类固醇对其进行治疗。目的是提高对这种不良反应的认识，因为它可能影响患者的生活质量并增加治疗中断率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ad9/8611763/6df627eef29e/cureus-0013-00000019024-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ad9/8611763/d2d67445afe3/cureus-0013-00000019024-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ad9/8611763/d2d67445afe3/cureus-0013-00000019024-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ad9/8611763/5f1561289f05/cureus-0013-00000019024-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ad9/8611763/6df627eef29e/cureus-0013-00000019024-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ad9/8611763/d2d67445afe3/cureus-0013-00000019024-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ad9/8611763/d2d67445afe3/cureus-0013-00000019024-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ad9/8611763/5f1561289f05/cureus-0013-00000019024-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ad9/8611763/6df627eef29e/cureus-0013-00000019024-i04.jpg

相似文献

1
Dasatinib-Induced Pleural and Pericardial Effusions.达沙替尼引起的胸腔和心包积液。
Cureus. 2021 Oct 25;13(10):e19024. doi: 10.7759/cureus.19024. eCollection 2021 Oct.
2
Pleural effusions due to dasatinib.达沙替尼引起的胸腔积液。
Curr Opin Pulm Med. 2010 Jul;16(4):351-6. doi: 10.1097/MCP.0b013e328338c486.
3
Recurrent Chylous Pleural Effusions in a Patient Treated With Dasatinib.达沙替尼治疗患者出现复发性乳糜性胸腔积液
Cureus. 2022 Aug 8;14(8):e27778. doi: 10.7759/cureus.27778. eCollection 2022 Aug.
4
HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.慢性髓性白血病、达沙替尼治疗下 BCR::ABL1 阳性患者中 HHV8 阴性原发性渗出性大 B 细胞淋巴瘤：新病例报告及文献复习。
Diagn Cytopathol. 2022 Dec;50(12):E351-E356. doi: 10.1002/dc.25027. Epub 2022 Aug 2.
5
Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP.慢性期慢性髓性白血病患者在达沙替尼治疗过程中出现的胸腔积液不伴有腹水。
Pleura Peritoneum. 2024 Feb 28;9(1):39-43. doi: 10.1515/pp-2023-0016. eCollection 2024 Mar.
6
Dasatinib-induced pleural effusions, pericardial effusion and pulmonary arterial hypertension: a case report.达沙替尼引起的胸腔积液、心包积液和肺动脉高压：一例报告
Transl Pediatr. 2024 Apr 30;13(4):673-681. doi: 10.21037/tp-23-517. Epub 2024 Apr 15.
7
Dasatinib-Induced Bilateral Pleural Effusions.达沙替尼诱发双侧胸腔积液。
Cureus. 2022 Apr 7;14(4):e23906. doi: 10.7759/cureus.23906. eCollection 2022 Apr.
8
New Developments in Chronic Myeloid Leukemia: Implications for Therapy.慢性髓性白血病的新进展：对治疗的启示
Iran J Cancer Prev. 2016 Feb 22;9(1):e3961. doi: 10.17795/ijcp-3961. eCollection 2016 Feb.
9
Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib.达沙替尼治疗的慢性髓性白血病合并 HIV 阴性原发性渗出性淋巴瘤。
Pathobiology. 2023;90(5):356-364. doi: 10.1159/000530429. Epub 2023 Mar 30.
10
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.慢性髓性白血病患者在接受每天 100 毫克或 50 毫克达沙替尼治疗时发生广泛的胸腔和心包积液。
Haematologica. 2011 Jan;96(1):163-6. doi: 10.3324/haematol.2010.030494. Epub 2010 Oct 7.

引用本文的文献

1
Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.跨领域文本挖掘以预测慢性髓性白血病酪氨酸激酶抑制剂的不良事件
Cancers (Basel). 2022 Sep 26;14(19):4686. doi: 10.3390/cancers14194686.

本文引用的文献

1
Association of tuberculosis in patients with chronic myeloid leukemia: a treatment proposal based on literature review.慢性髓性白血病患者合并结核病：基于文献综述的治疗建议
Expert Rev Hematol. 2021 Feb;14(2):211-217. doi: 10.1080/17474086.2021.1875818. Epub 2021 Jan 21.
2
Dasatinib induced pleuro-pericardial effusion.达沙替尼诱发了胸膜心包积液。
Acta Biomed. 2020 Mar 19;91(1):142-143. doi: 10.23750/abm.v91i1.8914.
3
Dasatinib Induced Cardiac Tamponade-A Rare Association.达沙替尼诱发心脏压塞——一种罕见的关联。
J Clin Diagn Res. 2017 Feb;11(2):FD03-FD04. doi: 10.7860/JCDR/2017/24633.9418. Epub 2017 Feb 1.
4
The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.新型酪氨酸激酶抑制剂在慢性髓性白血病中的作用
Cancer J. 2016 Jan-Feb;22(1):40-50. doi: 10.1097/PPO.0000000000000165.
5
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.未选择的老年慢性髓性白血病患者在接受达沙替尼治疗期间胸腔积液的发生率、风险因素和处理。
Hematol Oncol. 2013 Jun;31(2):103-9. doi: 10.1002/hon.2020. Epub 2012 Jul 19.
6
Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.达沙替尼：用于治疗慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病的综述。
Drugs. 2011 Sep 10;71(13):1771-95. doi: 10.2165/11207580-000000000-00000.
7
Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.接受低剂量达沙替尼治疗的慢性髓性白血病患者的胸腔和心包积液
Haematologica. 2011 Mar;96(3):e15; author reply e16-7. doi: 10.3324/haematol.2011.040048.
8
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.慢性髓性白血病患者在接受每天 100 毫克或 50 毫克达沙替尼治疗时发生广泛的胸腔和心包积液。
Haematologica. 2011 Jan;96(1):163-6. doi: 10.3324/haematol.2010.030494. Epub 2010 Oct 7.
9
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.酪氨酸激酶抑制剂治疗慢性髓性白血病相关不良反应的管理。
Leukemia. 2011 Feb;25(2):201-10. doi: 10.1038/leu.2010.215. Epub 2010 Sep 23.
10
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.达沙替尼 100 毫克，每日一次，可最大程度减少慢性期慢性髓性白血病患者胸腔积液的发生，并且对发生胸腔积液的患者的疗效没有影响。
Cancer. 2010 Jan 15;116(2):377-86. doi: 10.1002/cncr.24734.